Revance Therapeutics, Inc. (NASDAQ:RVNC) Q3 2022 Results Conference Call November 8, 2022 4:30 PM ET

Company Participants

Jessica Serra - Head of Investor Relations & ESG

Mark Foley - Chief Executive Officer

Dustin Sjuts - President

Tobin Schilke - Chief Financial Officer & Principal Accounting Officer

Conference Call Participants

Chris Shibutani - Goldman Sachs

Ken Cacciatore - Cowen

David Amsellem - Piper Sandler

Stacy Lee - Stifel

Justin Phillips - Morgan Stanley

Rohit Bhasin - Needham & Company

Operator

Welcome to the Revance Therapeutics Third Quarter 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. Following managements' prepared remarks, we will hold a question-and-answer session. [Operator Instructions] As a reminder, this call is being recorded today, Tuesday, November 8, 2022.

I would now like to turn the conference call over to Jessica Serra, Head of Investor Relations and ESG for Revance. Please go ahead.

Jessica Serra

Thank you, Daniel. Joining us on the call today from Revance are Chief Executive Officer, Mark Foley; President, Dustin Sjuts; and Chief Financial Officer, Toby Schilke. During this conference call, management will make forward-looking statements, including statements related to our regulatory submissions and approvals, consumer preferences and behavior, the benefits to us, practices and consumers of our products, 2022 guidance, cash flow breakeven, future capital expenditures and capital allocation plans, our ability to draw on our debt, our ability to effectively compete, our blockbuster and growth potential, the supply and manufacture of DAXXIFY, the impact of economic headwinds on our business and consumers and our strategy, planned operations and commercialization plans and timing.

Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. Factors that could cause results to be different from these statements include factors the Company describes in the section titled Risk Factors in our quarterly report on Form 10-Q filed with the SEC today, November 8, 2022. Revance undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events or changes in its expectations.

With that, I will turn the call over to Mark Foley, Chief Executive Officer of Revance. Mark?

Mark Foley

Thank you, Jessica. Good afternoon, everyone, and thank you for joining our third quarter 2022 financial results conference call. The third quarter of this year marked an inflection point for the Company given the FDA's approval of DAXXIFY, the first and only long-acting peptide formulated neuromodulator for glabellar lines. This significant milestone positions Revance as the innovation leader in facial injectables and will enable us to realize our blockbuster potential in the U.S. aesthetics market. We're also providing the foundation for our sBLA submission for cervical dystonia, our first therapeutic indication.